Introduction
In 1841, William West wrote a now well-known, oftquoted letter to the Lancet in which he described his infant son's "peculiar form of infantile convulsions" [1] . However, case reports of infantile spasms (IS) remained rare until the 1920s. With the identification of hypsarrhythmia on electroencephalogram (EEG) in 1952, West syndrome became recognized and subsequently diagnosed as the triad of hypsarrhythmia, IS, and developmental arrest. Nevertheless, although much has been learned about spasms in the interim, fundamental questions of pathogenesis and treatment persist. Outcomes all too often remain dismal, with long-term mental retardation developing in 70% to 85% of patients and more than 50% developing Lennox-Gastaut syndrome [2] .
IS are myoclonic seizures characterized by a brief contraction, followed by a more sustained tonic phase. They can involve extensor, flexor, or mixed postures. With large spasms the entire body seems to "jack-knife" forward at the waist, but more subtle manifestations with eye deviation, head bobbing, asymmetric posturing, or behavioral arrest are common and may be the only manifestation. The spasms often occur in clusters and seem to increase upon awakening. The EEG demonstrates hypsarrhythmia-a high-voltage, diffuse, posterior maximum pattern of slow, multifocal spike waves with periods of electrodecremental suppression.
IS are not uncommon, occurring in one of 3225 births [3•]. The peak of onset is at 6 months, and most cases (94%) begin in the first year [4•]. Infants with normal development before spasm onset and without identifiable causes are classified as "cryptogenic" (10% to 25%) [5] . Cases in which there are known etiologies are classified as "symptomatic" (75% to 90%), a percentage that continues to increase with improving diagnostic capacities. A recent review of the literature yielded more than 200 conditions associated with spasms [3•]. How such diverse conditions can result in a stereotyped syndrome remains unclear. Generally, cryptogenic cases carry a more favorable prognosis.
The underlying physiologies of the seizures and the encephalopathy are the subject of research and debate. There are proponents of cortical, subcortical, basal ganglia, thalamic, and brainstem origins for the seizures [6] . Moreover, controversy exists as to whether the hypsarrhythmia represents severely disordered background, or actually a form of status epilepticus. Given the broad spectrum of etiologies and age-dependent, fairly stereotypic features of West syndrome, there is some reason to suspect a final common pathway for the disorder. Theoretical models for a developmental insult of synaptogenesis, myelination, or neurotransmitter systems (eg, glutamate or serotonin) have been explored.
Opinion statement
Infantile spasms are associated with a diverse range of conditions, and treatment options are available. However, outcomes remain generally poor, particularly for those with symptomatic etiologies. First-line therapy is considered to be hormonal (adrenocorticotropic hormone; ACTH), which some evidence suggests is more effective when started early. However, side effects may place limits on its use acutely and long-term. There is additional evidence for vigabatrin, specifically for infantile spasms secondary to tuberous sclerosis complex. In refractory cases, candidacy for surgical management should be explored, along with new-generation anticonvulsants (eg, topiramate, zonisamide) and the ketogenic diet. There is urgent need for further treatment trials comparing anticonvulsants with ACTH and a satisfactory animal model for the study of spasms.
Immune-mediated mechanisms and overproduction of corticotrophin-releasing hormone have also been proposed [4•,7•,8] . Nevertheless, the absence of an animal model for IS has made advances into the pathogenesis difficult to say the least, and the search for such a model is an active area of investigation [9] .
The best treatment for IS remains controversial. Firstline therapy in the United States is synthetic adrenocorticotropic hormone (ACTH) [10••,11•] . A recent American Academy of Neurology (AAN) practice parameter concluded that ACTH is probably effective in the treatment of IS, with insufficient evidence to recommend a particular regimen (ie, high or low dose) [10••] . The same review concluded that oral corticosteroids were less effective than ACTH in the treatment of spasms, and vigabatrin is possibly effective. Studies referred to in this parameter demonstrate a range of spasm freedom in approximately 40% to 80% of patients [10••] . Several studies reported full cessation of spasms in the first 2 weeks of therapy, an all-or-none effect that is commonly reported in the literature. Vigabatrin is probably effective for tuberous sclerosis complex-associated spasms, for which it may be the treatment of choice. However, the incidence of associated permanent visual field defects with long-term use led to the US Food and Drug Administration (FDA) withdrawing it from the market. This may change in the near future. There is also evidence in rats that increased ␥-aminobutyric acid (GABA) concentration in the developing brain (as found with vigabatrin use) may be associated with neuronal apoptosis and axonal degeneration [12••] .
Although there is insufficient evidence to suggest the optimal dose and duration of ACTH, the typical dose in North America (Snead Protocol, see later text) is favored on the basis of demonstrated efficacy at higher doses [10••] . Other studies [13] , particularly from Europe and Japan, have demonstrated efficacy at lower dosages (Japan: 3-14 IU/day; Finland: 18-36 IU/day), and it has been suggested that long-term outcomes may be better in the low-dose ACTH groups (see later text) [12••] . Incidence of relapse after ACTH ranges from 15% to 50%. There are insufficient data on the relapse rate with vigabatrin. The rate of patients who were seizure free at 3 to 4 months after ACTH and vigabatrin was comparable (42% to 44%). If a first course of ACTH is unsuccessful or seizures recur, we think the next step is to give a second course of ACTH or consider other options such as vigabatrin, other anticonvulsants, surgery, or the ketogenic diet [14•; 15, Class III; 16] .
Regarding outcomes, the AAN parameter concluded that long-term outcomes evaluated in Class III and IV studies reviewed provided insufficient evidence that treatment-including early treatment-improves longterm cognitive outcome or reduces the incidence of subsequent epilepsy. However, a Finnish cohort of 214 patients that was not included in the review showed that cognitive outcomes were better in both cryptogenic and symptomatic patients who were treated early (< 6 weeks) and who responded to ACTH [17] . Moreover, improved outcomes were noted in patients who received smaller doses of ACTH (20-40 IU/day vs 120 IU/day). A separate study showed normal cognitive outcomes in cryptogenic patients specifically if treated within 1 month of onset of spasms [18] .
Outside of brief (1-2 months) treatment with hormonal therapy, the appropriate duration of treatment with other therapies has been given limited attention in the literature. One group advocates early cessation of therapy with resolution of spasms [19] . Given the desired all-or-none response and possibly improved outcomes with earlier treatment of spasms, it is reasonable to change to an additional or different therapy after 4 to 8 weeks of inefficacy with the first therapyprovided adequate dosing is used. 
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